Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Demographic, Clinical, and Investigational Characteristics of COVID-19- related Guillain-Barré Syndrome with Differences from Typical and Another Virus-related Guillain-Barré Syndrome

Author(s): Jitendra Singh, Nilesh Kumar and Anju Dinkar*

Volume 22, Issue 7, 2022

Published on: 24 June, 2022

Article ID: e290422204292 Pages: 12

DOI: 10.2174/1871526522666220429134113

Price: $65

Abstract

Backgrounds: SARS-CoV-2 infection typically presents with fever and respiratory symptoms. Besides this, COVID-19-related central and peripheral nervous system manifestations are emerging.

Objectives: This study summarises the demographics, clinical profiles, laboratory findings, management strategies, and outcomes in a large number of patients with COVID-19-related GBS and its variants. We also compared its clinical profile with Zika and dengue virus-related GBS.

Methods: The authors carried out a literature search up to Dec 31, 2020, in MEDLINE, PubMed, SCOPUS, Cochrane database, and Google Scholar for all published articles.

Results: The study identified 54 different types of articles consisting of 70 cases from 17 countries worldwide. A maximum of 15 cases (21.4 %) were identified from Italy, followed by the USA (12; 17.1 %), Spain (11; 15.7 %), and Iran (10; 14.3 %). The age group that was more than 60 years had the most cases, i.e., 32 (45.7 %), followed by the age group 40-60 with 25 cases (35.7 %) with a male to female ratio of 2. Maximum cases were treated with IVIG infusion 58 (82.9 %), followed by Plasma exchange 13 (18.6 %) cases. Out of 70 cases, 7 (10 %) cases were manifested as Miller-Fisher syndrome. The most predominant electrodiagnostic variant was demyelinating neuropathy in 41 (73.21 %) cases. The outcome reported in 67 cases was survival in 63 (90 %) cases and death in 4 (5.7 %) cases.

Conclusion: Covid-19-related GBS were reported worldwide with a better outcome. Both postinfectious and parainfectious patterns were reported. Early recognition with prompt management of GBS can prevent further severe morbidity and mortality.

Keywords: Miller-Fisher syndrome, intravenous immunoglobulin, plasmapheresis, SARS-CoV-2, COVID-19, AIDP.

Graphical Abstract

[1]
Acherjya GK, Rahman MM, Islam MT, et al. Acute pancreatitis in a COVID-19 patient: An unusual presentation. Clin Case Rep 2020; 8(12): 3400-7.
[http://dx.doi.org/10.1002/ccr3.3412] [PMID: 33363941]
[2]
Abd-Elsalam S, Salama M, Soliman S, et al. Remdesivir efficacy in COVID-19 treatment: A randomized controlled trial. Am J Trop Med Hyg 2021; 106(3): 886-90.
[http://dx.doi.org/10.4269/ajtmh.21-0606] [PMID: 34649223]
[3]
Dabbous HM, Abd-Elsalam S, El-Sayed MH, et al. Efficacy of favipiravir in COVID-19 treatment: A multi-center randomized study. Arch Virol 2021; 166(3): 949-54.
[http://dx.doi.org/10.1007/s00705-021-04956-9] [PMID: 33492523]
[4]
Abd-Elsalam S, Soliman S, Esmail ES, et al. Do zinc supplements enhance the clinical efficacy of hydroxychloroquine?: A randomized, multicenter trial. Biol Trace Elem Res 2021; 199(10): 3642-6.
[http://dx.doi.org/10.1007/s12011-020-02512-1] [PMID: 33247380]
[5]
Abd-Elsalam S, Noor RA, Badawi R, et al. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized con-trolled study. J Med Virol 2021; 93(10): 5833-8.
[http://dx.doi.org/10.1002/jmv.27122] [PMID: 34076901]
[6]
Payus AO, Liew Sat Lin C, Mohd Noh M, Jeffree MS, Ali RA. SARS-CoV-2 infection of the nervous system: A review of the literature on neurological involvement in novel coronavirus disease-(COVID-19). Bosn J Basic Med Sci 2020; 20(3): 283-92.
[http://dx.doi.org/10.17305/bjbms.2020.4860] [PMID: 32530389]
[7]
Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in wuhan, China. JAMA Neurol 2020; 77(6): 683-90.
[http://dx.doi.org/10.1001/jamaneurol.2020.1127] [PMID: 32275288]
[8]
Rahimi K. Guillain-Barre syndrome during COVID-19 pandemic: An overview of the reports. Neurol Sci 2020; 41(11): 3149-56.
[http://dx.doi.org/10.1007/s10072-020-04693-y] [PMID: 32876777]
[9]
Uncini A, Vallat J-M, Jacobs BC. Guillain-Barré syndrome in SARS-CoV-2 infection: An instant systematic review of the first six months of pandemic. J Neurol Neurosurg Psychiatry 2020; 91(10): 1105-10.
[http://dx.doi.org/10.1136/jnnp-2020-324491] [PMID: 32855289]
[10]
Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: Causality or coincidence? Lancet Neurol 2020; 19(5): 383-4.
[http://dx.doi.org/10.1016/S1474-4422(20)30109-5] [PMID: 32246917]
[11]
Hauser SL, Amato AA. Guillain-Barré syndrome and other Immune- Mediated Neuropathies. In: Jameson JL, Kasper DL, Longo DL, Fauci AS, Hauser SL, Loscalzo J, Eds. Harrison’s Principles of Internal Medicine, 20th Ed. New York: McGraw Hill.2018; pp. 3225-32.
[12]
Kumar S, Nyodu R, Maurya VK, Saxena SK. Morphology, genome organization, replication, and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus Disease 2019 (COVID-19) 2020; 30: 23-31.
[13]
Chan JL, Ebadi H, Sarna JR. Guillain-Barré syndrome with facial diplegia related to SARS-CoV-2 infection. Can J Neurol Sci 2020; 47(6): 852-4.
[http://dx.doi.org/10.1017/cjn.2020.106] [PMID: 32468972]
[14]
Oguz-Akarsu E, Ozpar R, Mirzayev H, et al. Guillain-barré syndrome in a patient with minimal symptoms of COVID-19 infection. Muscle Nerve 2020; 62(3): E54-7.
[http://dx.doi.org/10.1002/mus.26992] [PMID: 32497292]
[15]
Angelo B, Angelo MC, Matteo C, et al. Atypical clinical presentation of COVID-19: A case of Guillain-Barrè Syndrome related to SARS-Cov-2 infection. Curr Tr Clin Med Sci 2020; 2(1): 125-8.
[16]
Mozhdehipanah H, Paybast S, Gorji R. Guillain-Barr’e syndrome as a neurological complication of COVID-19 infection: A case series and review of the literature. Int Clin Neurosci J 2020; 7(3): 156-61.
[http://dx.doi.org/10.34172/icnj.2020.18]
[17]
Caress JB, Castoro RJ, Simmons Z, et al. COVID-19-associated Guillain-Barré syndrome: The early pandemic experience. Muscle Nerve 2020; 62(4): 485-91.
[http://dx.doi.org/10.1002/mus.27024] [PMID: 32678460]
[18]
Padroni M, Mastrangelo V, Asioli GM, et al. Guillain-Barré syndrome following COVID-19: New infection, old complication? J Neurol 2020; 267(7): 1877-9.
[http://dx.doi.org/10.1007/s00415-020-09849-6] [PMID: 32333166]
[19]
Marta-Enguita J, Rubio-Baines I, Gastón-Zubimendi I. Fatal Guillain-Barre syndrome after infection with SARS-CoV-2. Neurologia 2020; 35(4): 265-7.
[http://dx.doi.org/10.1016/j.nrleng.2020.04.004] [PMID: 32364124]
[20]
Alberti P, Beretta S, Piatti M, et al. Guillain-Barré syndrome related to COVID-19 infection. Neurol Neuroimmunol Neuroinflamm 2020; 7(4): e741.
[http://dx.doi.org/10.1212/NXI.0000000000000741] [PMID: 32350026]
[21]
Diez-Porras L, Vergés E, Gil F, Vidal MJ, Massons J, Arboix A. Guillain-Barré-Strohl syndrome and COVID-19: Case report and literature review. Neuromuscul Disord 2020; S0960-8966(20): 30551- 4.
[http://dx.doi.org/10.1016/j.nmd.2020.08.354]
[22]
McGonagle D, Ramanan AV, Bridgewood C. Immune cartography of macrophage activation syndrome in the COVID-19 era. Nat Rev Rheumatol 2021; 17(3): 145-57.
[http://dx.doi.org/10.1038/s41584-020-00571-1] [PMID: 33547426]
[23]
Toscano G, Palmerini F, Ravaglia S, et al. Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med 2020; 382(26): 2574-6.
[http://dx.doi.org/10.1056/NEJMc2009191] [PMID: 32302082]
[24]
Zito A, Alfonsi E, Franciotta D, et al. COVID-19 and Guillain-Barré syndrome: A case report and review of literature. Front Neurol 2020; 11: 909.
[http://dx.doi.org/10.3389/fneur.2020.00909] [PMID: 32973665]
[25]
Assini A, Benedetti L, Di Maio S, Schirinzi E, Del Sette M. New clinical manifestation of COVID-19 related Guillain-Barrè syndrome highly responsive to intravenous immunoglobulins: Two Italian cases. Neurol Sci 2020; 41(7): 1657-8.
[http://dx.doi.org/10.1007/s10072-020-04484-5] [PMID: 32468450]
[26]
Lantos JE, Strauss SB, Lin E. COVID-19-associated miller fisher syndrome: MRI findings. AJNR Am J Neuroradiol 2020; 41(7): 1184-6.
[http://dx.doi.org/10.3174/ajnr.A6609] [PMID: 32467190]
[27]
Gutiérrez-Ortiz C, Méndez-Guerrero A, Rodrigo-Rey S, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology 2020; 95(5): e601-5.
[http://dx.doi.org/10.1212/WNL.0000000000009619] [PMID: 32303650]
[28]
Zhang G, Li Q, Zhang R, Wei X, Wang J, Qin X. Subtypes and prognosis of Guillain-Barré syndrome in southwest China. PLoS One 2015; 10(7): e0133520.
[http://dx.doi.org/10.1371/journal.pone.0133520]
[29]
Chan M, Han SC, Kelly S, Tamimi M, Giglio B, Lewis A. A case series of Guillain-Barré Syndrome following COVID-19 infection in New York. Neurol Clin Pract 2020; 11(4): 576-8.
[30]
Pfefferkorn T, Dabitz R, von Wernitz-Keibel T, Aufenanger J, Nowak-Machen M, Janssen H. Acute polyradiculoneuritis with locked-in syndrome in a patient with COVID-19. J Neurol 2020; 267(7): 1883-4.
[http://dx.doi.org/10.1007/s00415-020-09897-y] [PMID: 32399694]
[31]
Helbok R, Beer R, Löscher W, et al. Guillain-Barré syndrome in a patient with antibodies against SARS-COV-2. Eur J Neurol 2020; 27(9): 1754-6.
[http://dx.doi.org/10.1111/ene.14388] [PMID: 32531083]
[32]
Hutchins KL, Jansen JH, Comer AD, et al. COVID-19-Associated bifacial weakness with paresthesia subtype of Guillain-Barré syndrome. AJNR Am J Neuroradiol 2020; 41(9): 1707-11.
[http://dx.doi.org/10.3174/ajnr.A6654] [PMID: 32586958]
[33]
Abrams RMC, Kim BD, Markantone DM, et al. Severe rapidly progressive Guillain-Barré syndrome in the setting of acute COVID-19 dis-ease. J Neurovirol 2020; 26(5): 797-9.
[http://dx.doi.org/10.1007/s13365-020-00884-7] [PMID: 32720233]
[34]
Paybast S, Gorji R, Mavandadi S. Guillain-Barré syndrome as a neurological complication of novel COVID-19 infection: A case report and review of the literature. Neurologist 2020; 25(4): 101-3.
[http://dx.doi.org/10.1097/NRL.0000000000000291] [PMID: 32618839]
[35]
Solomon IH, Normandin E, Bhattacharyya S, et al. Neuropathological features of COVID-19. N Engl J Med 2020; 383(10): 989-92.
[http://dx.doi.org/10.1056/NEJMc2019373] [PMID: 32530583]
[36]
Leis AA, Stokic DS. Neuromuscular manifestations of west nile virus infection. Front Neurol 2012; 3: 37.
[http://dx.doi.org/10.3389/fneur.2012.00037] [PMID: 22461779]
[37]
Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: A case report. J Clin Neurosci 2020; 76: 233-5.
[http://dx.doi.org/10.1016/j.jocn.2020.04.062] [PMID: 32312628]
[38]
Virani A, Rabold E, Hanson T, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection. IDCases 2020; 20: e00771.
[http://dx.doi.org/10.1016/j.idcr.2020.e00771] [PMID: 32313807]
[39]
Camdessanche JP, Morel J, Pozzetto B, Paul S, Tholance Y, Botelho-Nevers E. COVID-19 may induce Guillain-Barré syndrome. Rev Neurol 2020; 176(6): 516-8.
[http://dx.doi.org/10.1016/j.neurol.2020.04.003] [PMID: 32334841]
[40]
Scheidl E, Canseco DD. HadjiNaumov A, Bereznai B. Guillain-Barré syndrome during SARS-CoV-2 pandemic: A case report and review of recent literature. J Peripher Nerv Syst 2020; 25(2): 204-7.
[41]
El Otmani H, El Moutawakil B, Rafai MA, et al. Covid-19 and Guillain-Barré syndrome: More than a coincidence. Rev Neurol 2020; 176(6): 518-9.
[http://dx.doi.org/10.1016/j.neurol.2020.04.007] [PMID: 32359804]
[42]
Naddaf E, Laughlin RS, Klein CJ, et al. Guillain-Barré syndrome in a patient with evidence of recent SARS-CoV-2 infection. Mayo Clin Proc 2020; 95(8): 1799-801.
[http://dx.doi.org/10.1016/j.mayocp.2020.05.029] [PMID: 32753154]
[43]
Coen M, Jeanson G, Culebras Almeida LA, et al. Guillain-Barré syndrome as a complication of SARS-CoV-2 infection. Brain Behav Immun 2020; 87: 111-2.
[http://dx.doi.org/10.1016/j.bbi.2020.04.074] [PMID: 32360440]
[44]
Caamaño JDS, Beato RA. Facial diplegia, a possible atypical variant of Guillain-Barré Syndrome as a rare neurological complication of SARS-CoV-2. J Clin Neurosci 2020; 77: 230-2.
[http://dx.doi.org/10.1016/j.jocn.2020.05.016] [PMID: 32410788]
[45]
Tiet MY, AlShaikh N. Guillain-Barré syndrome associated with COVID-19 infection: A case from the UK. BMJ Case Rep 2020; 13(7): e236536.
[http://dx.doi.org/10.1136/bcr-2020-236536] [PMID: 32641309]
[46]
Ottaviani D, Boso F, Tranquillini E, et al. Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): A case report from an Italian COVID-hospital. Neurol Sci 2020; 41(6): 1351-4.
[http://dx.doi.org/10.1007/s10072-020-04449-8] [PMID: 32399950]
[47]
Riva N, Russo T, Falzone YM, et al. Post-infectious Guillain-Barré syndrome related to SARS-CoV-2 infection: A case report. J Neurol 2020; 267(9): 2492-4.
[http://dx.doi.org/10.1007/s00415-020-09907-z] [PMID: 32458192]
[48]
Webb S, Wallace VC, Martin-Lopez D, Yogarajah M. Guillain-Barré syndrome following COVID-19: A newly emerging post-infectious complication. BMJ Case Rep 2020; 13(6): e236182.
[http://dx.doi.org/10.1136/bcr-2020-236182] [PMID: 32540883]
[49]
Ebrahimzadeh SA, Ghoreishi A, Rahimian N. Guillain-Barré syndrome associated with the coronavirus disease 2019 (COVID-19). Neurol Clin Pract 2021; 11(2): e196-8.
[http://dx.doi.org/10.1212/CPJ.0000000000000879]
[50]
Dinkin M, Gao V, Kahan J, et al. COVID-19 presenting with ophthalmoparesis from cranial nerve palsy. Neurology 2020; 95(5): 221-3.
[http://dx.doi.org/10.1212/WNL.0000000000009700] [PMID: 32358218]
[51]
Galán AV, Saucedo PDS, Postigo FP, Paniagua EB. Guillain Barré syndrome associated with SARS CoV 2 infection. Neurologia 2020; 35(4): 268-9.
[52]
Arnaud S, Budowski C, Ng Wing Tin S, Degos B. Post SARS-CoV-2 Guillain-Barré syndrome. Clin Neurophysiol 2020; 131(7): 1652-4.
[http://dx.doi.org/10.1016/j.clinph.2020.05.003] [PMID: 32422529]
[53]
Lampe A, Winschel A, Lang C, Steiner T. Guillain-Barré syndrome and SARS-CoV-2. Neurol Res Pract 2020; 2(1): 19.
[http://dx.doi.org/10.1186/s42466-020-00066-0] [PMID: 32835165]
[54]
Guijarro-Castro C, Rosón-González M, Abreu A, García-Arratibel A, Ochoa-Mulas M. Guillain-Barré syndrome associated with SARS-CoV-2 infection. Comments after 16 published cases. Neurologia 2020; 35(6): 412-5.
[http://dx.doi.org/10.1016/j.nrl.2020.06.002]
[55]
Bigaut K, Mallaret M, Baloglu S, et al. Guillain-Barré syndrome related to SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm 2020; 7(5): e785.
[http://dx.doi.org/10.1212/NXI.0000000000000785] [PMID: 32461235]
[56]
Sharma K, Tengsupakul S, Sanchez O, Phaltas R, Maertens P. Guillain-Barré syndrome with unilateral peripheral facial and bulbar palsy in a child: A case report SAGE Open Med Case Rep 2019; 7: 2050313X19838750.
[http://dx.doi.org/10.1177/2050313X19838750]
[57]
Khalifa M, Zakaria F, Ragab Y, et al. Guillain-Barré syndrome associated with severe acute respiratory syndrome coronavirus 2 detection and coronavirus disease 2019 in a child. J Pediatric Infect Dis Soc 2020; 9(4): 510-3.
[http://dx.doi.org/10.1093/jpids/piaa086] [PMID: 32652520]
[58]
Farzi MA, Ayromlou H, Jahanbakhsh N, Bavil PH, Janzadeh A, Shayan FK. Guillain-Barré syndrome in a patient infected with SARS-CoV-2, a case report. J Neuroimmunol 2020; 346: 577294.
[http://dx.doi.org/10.1016/j.jneuroim.2020.577294] [PMID: 32590125]
[59]
Su XW, Palka SV, Rao RR, Chen FS, Brackney CR, Cambi F. SARS-CoV-2-associated Guillain-Barré syndrome with dysautonomia. Muscle Nerve 2020; 62(2): E48-9.
[http://dx.doi.org/10.1002/mus.26988] [PMID: 32445201]
[60]
Kilinc D, van de Pasch S, Doets AY, Jacobs BC, van Vliet J, Garssen MPJ. Guillain-Barré syndrome after SARS-CoV-2 infection. Eur J Neurol 2020; 27(9): 1757-8.
[http://dx.doi.org/10.1111/ene.14398] [PMID: 32533876]
[61]
Molina EA, Martínez MM, Chueca SP, López CA, Val SI, Sanjuan-Villarreal TA. Guillain-Barré syndrome associated with SARS-CoV-2 infection. Med Intensiva 2020; 44(8): 513-4.
[http://dx.doi.org/10.1016/j.medine.2020.04.006] [PMID: 32532531]
[62]
Rana S, Lima AA, Chandra R, et al. Novel coronavirus (COVID-19)-associated guillainbarré syndrome: Case report. J Clin Neuromuscul Dis 2020; 21(4): 240-2.
[http://dx.doi.org/10.1097/CND.0000000000000309] [PMID: 32453100]
[63]
Reyes-Bueno JA, García-Trujillo L, Urbaneja P. SCiano-Petersen NL, Postigo- Pozo MJ, Martínez-Tomás C. Miller-Fisher syndrome after SARS-CoV-2 infection. Eur J Neurol 2020; 27(9): 1759-61.
[http://dx.doi.org/10.1111/ene.14383]
[64]
Sancho-Saldaña A, Lambea-Gil Á, Liesa JLC, et al. Guillain-Barré syndrome associated with leptomeningeal enhancement following SARS-CoV-2 infection. Clin Med 2020; 20(4): e93-4.
[http://dx.doi.org/10.7861/clinmed.2020-0213] [PMID: 32518103]
[65]
Busillo V, Lerza MC, Gargiulo MG, et al. A case of Guillain-Barrè syndrome associated with SARS-CoV-2 infection. Pharmacologyonline 2020; 2: 321-4.
[66]
Frank CHM, Almeida TVR, Marques EA, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection in a pediatric patient. J Trop Pediatr 2021; 67(3): fmaa044.
[http://dx.doi.org/10.1093/tropej/fmaa044]
[67]
Agosti E, Giorgianni A, D’Amore F, Vinacci G, Balbi S, Locatelli D. Is Guillain-Barrè syndrome triggered by SARS-CoV-2? Case report and literature review. Neurol Sci 2021; 42(2): 607-12.
[http://dx.doi.org/10.1007/s10072-020-04553-9] [PMID: 32643136]
[68]
Rajdev K, Victor N, Buckholtz ES, et al. A case of Guillain-Barré syndrome associated with COVID-19. J Investig Med High Impact Case Rep 2020; 8: 2324709620961198.
[http://dx.doi.org/10.1177/2324709620961198] [PMID: 32981333]
[69]
Korem S, Gandhi H, Dayag DB. Guillain-Barré syndrome associated with COVID-19 disease. BMJ Case Rep 2020; 13(9): e237215.
[http://dx.doi.org/10.1136/bcr-2020-237215] [PMID: 32958554]
[70]
Lascano AM, Epiney JB, Coen M, et al. SARS-CoV-2 and Guillain-Barré syndrome: AIDP variant with a favourable outcome. Eur J Neurol 2020; 27(9): 1751-3.
[http://dx.doi.org/10.1111/ene.14368] [PMID: 32478936]
[71]
Fernández-Domínguez J, Ameijide-Sanluis E, García-Cabo C, García-Rodríguez R, Mateos V. Miller-Fisher-like syndrome related to SARS-CoV-2 infection (COVID 19). J Neurol 2020; 267(9): 2495-6.
[http://dx.doi.org/10.1007/s00415-020-09912-2] [PMID: 32458195]
[72]
Dirlikov E, Major CG, Medina NA, et al. Clinical features of Guillain-Barré syndrome with vs without Zika virus infection, Puerto Rico, 2016. JAMA Neurol 2018; 75(9): 1089-97.
[http://dx.doi.org/10.1001/jamaneurol.2018.1058] [PMID: 29799940]
[73]
Simon O, Billot S, Guyon D, et al. Early Guillain-Barré Syndrome associated with acute dengue fever. J Clin Virol 2016; 77: 29-31.
[http://dx.doi.org/10.1016/j.jcv.2016.01.016] [PMID: 26895226]

Rights & Permissions Print Cite
Article Metrics
27
2
© 2024 Bentham Science Publishers | Privacy Policy